Orionis Biosciences has announced a second collaboration with Genentech, worth $105 million upfront and up to $2 billion in potential milestone payments, to develop small-molecule glue medicines for oncology targets....Learn more| Orionis Biosciences
Dose-escalation study to evaluate ORB-011 as single agent, with initial safety, pharmacokinetic and mechanism-based pharmacodynamic readouts. Tony Fadell, inventor of the iPod, co-inventor of the iPhone, founder of Nest, and Principal at Build Collective, joins Orionis Board of Directors. November 15, 2023, BOSTON, MA, and GHENT, Belgium – Orionis Biosciences, a life sciences company pioneering... Learn more The post Orionis Biosciences Announces First Patient Dosed in Phase 1 Clinical Tria...| Orionis Biosciences
... Learn more The post Learning about molecular glues from the CEO of Orionis Biosciences following a recent Genentech deal appeared first on Orionis Biosciences.| Orionis Biosciences
... Learn more The post Genentech sticks molecular glue deal with Orionis for $47M upfront appeared first on Orionis Biosciences.| Orionis Biosciences
... Learn more The post Genentech gets gluey, paying $47M upfront to Orionis for degrader discovery deal appeared first on Orionis Biosciences.| Orionis Biosciences
In this episode of Breakthrough Economy, we discuss biotech innovations and challenges in the immuno-oncology space. Host Jen Rogers is joined by Niko Kley, co-founder and CEO of Orionis Biosciences and Dr. Pam Sharma, Professor and Director of Scientific Programs for the James P. Allison Institute at MD Anderson Cancer Center.... Learn more The post Orionis Featured in Nasdaq Breakthrough Economy appeared first on Orionis Biosciences.| Orionis Biosciences
Boston, MA & Ghent, Belgium – Orionis Biosciences, a life sciences company pioneering innovation of highly selective and tunable therapeutics for cancer and beyond, today presented preclinical data supporting its A-Kine™ platform for rational design of cis-acting immuno-cytokines at the 14th Annual PEGS Europe Protein & Antibody Engineering Summit, taking place November 14 – 16... Learn more The post Orionis Biosciences Presents Preclinical Data on Interferon and IL-2 Targeted Cytokine ...| Orionis Biosciences
Boston, MA and Ghent, Belgium – Orionis Biosciences, a life sciences company pioneering innovation of highly selective and tunable therapeutics for cancer and beyond, today will present preclinical data supporting its Allo-GlueTM protein degradation platform for discovery and rational design of small molecule molecular glues at the 5th Annual Targeted Protein Degradation Summit, taking place... Learn more The post Orionis Biosciences Demonstrates Platform Capabilities of Genome-scale Molecu...| Orionis Biosciences
In seven years, a small company has built two programs in immuno-oncology and molecular glues and got itself into a partnership with one of the world’s biggest pharma companies. Now the transatlantic biotech has refilled its coffers. Orionis Biosciences announced Wednesday morning that it finished a Series C round and secured $55 million. That infusion... Learn more The post Novartis-partnered Orionis secures $55M to push cytokine program into clinic appeared first on Orionis Biosciences.| Orionis Biosciences
Orionis to receive $47 million upfront, as well as future milestone-related payments. Orionis will leverage its Allo-Glue™ platform for discovery of small molecule monovalent glues. September 20, 2023, BOSTON, MA and GHENT, Belgium – Orionis Biosciences, a privately held life sciences company with an integrated drug discovery and chemical biology platform, announced today a multi-year...Learn more| Orionis Biosciences